

The 21st JFCR-ISCC

New Antitumor Agents under Development in the US, Europe and Japan



2016

December 14, (Wed)

13:00 - 17:15

December 15, (Thu)

9:00 - 17:50

Miraikan

National Museum of
Emerging Science and Innovation
2-3-6, Aomi, Koto-ku, Tokyo, Japan

Contact:
Cancer Chemotherapy Center,
Japanese Foundation for Cancer Research
jfc-r-iscc@ml.jfcr.or.jp

<http://iscc.umin.jp/>

Dec. 14

Recent progress in immuno-oncology

13:10-

Michael Axelson *Bristol-Myers Squibb*
Challenges in the development of immuno-oncology
agents and combinations

Lillian L. Siu *Princess Margaret Cancer Centre*
Immune co-stimulatory molecules alone or in combination
with immune checkpoint inhibitors in clinical trials

Recent developments of engineered antibodies

15:00 -

Nils Lonberg *Bristol-Myers Squibb*
Antibody based cancer immunotherapeutics

Takahiro Ishiguro *Chugai Pharmaceutical Co., Ltd.*
T cell redirecting bispecific antibody targeting Glypican3
-Next approach to cancer immunotherapy

Poster Session

16:15 -

Dec.15

Targeting DNA repair, checkpoint and epigenetic regulators

9:00 -

Yves G. Pommier *National Cancer Institute*
DNA repair genomic alterations and impact for precision
medicine

Makoto Nakanishi *Univ. of Tokyo*
Cancer-specific chemosensitizers targeting G2/M checkpoint

Issay Kitabayashi *National Cancer Center*
Novel leukemia stem cell-targeted therapy for acute
myeloid leukemia based on dual inhibition of EZH1/EZH2

Poster Discussion Session 11:00 - 12:00

Luncheon Seminar

12:10-

Yasutoshi Murayama *Kyoto Prefectural Univ. of
Medicine*
Photodynamic diagnosis and therapy of gastro intestinal
cancers using 5-aminolevulinic acid

Hideo Fukuhara *Kochi Medical School*
Photodynamic diagnosis of bladder and prostate cancers
using 5-aminolevulinic acid

Special Lecture

13:20-

Hiroyuki Mano *Univ. of Tokyo*
Targeting oncogenic fusion genes in cancer therapy

Protein knockdown as a novel antitumor strategy

14:40-

Craig M. Crews *Yale Univ.*
PROTACS: Induced protein degradation as an anti-tumor
therapeutic strategy

Mikihiko Naito *National Institute of Health Sciences*
In vivo protein knockdown by SNIPER recruiting IAP
ubiquitin ligases

Shuichi Ohkubo *Taiho Pharmaceutical Co., Ltd.*
Targeting Cullin-RING ubiquitin ligases by a highly potent
NEDD8-activating enzyme inhibitor, TAS4464

New targets and drugs under clinical or preclinical investigations

16:20-

Sai-Hong Ignatius Ou *Univ. of California*
Current status and future prospects of personalized
medicine of lung cancer

Toshio Yoshizawa *Ono Pharmaceutical Co., Ltd.*
Selective BTK inhibitor ONO-4059 with potent anti-tumor
activity in B-cell malignancies